Kornimate/medical-research-clean huggingface dataset:
neonatal jaundice: knowledge, attitudes and practices of mothers and medical trainees and providers in and around ogbomosho

Conditions: Neonatal Jaundice

Summary: determine the knowledge attitude and practices of all levels of health care providers about neonatal jaundice

during the routine post-natal visit, trained research personnel will inform the mother of the infant or medical practitioner that a study in being carried out to better understand the knowledge, attitudes and practices of mothers and health care providers for neonatal jaundice. the investigators will then proceed to ask the mothers or health care professionals if they would be interested in filling out an anonymous survey that will assess their knowledge of neonatal jaundice and their practices, if any, in caring for this condition. no phi will be included and no written consent will be obtained as the written consent would be the only link to the person participating in the survey. verbal consent will be obtained and we will explain that their medical care and care of the children will in no way be affected by their answers to the survey. we will carefully explain that their participation in the survey is voluntary. for medical students, they will be informed that a study is being carried out to better understand the knowledge, attitudes and practices of medical trainees for neonatal jaundice. they will then be asked if they would be interested in filling out an anonymous survey that assess their knowledge of neonatal jaundice, and their practices, if any, in caring for this condition. no phi will be included and no written consent will be obtained, as the written consent would be the only link to the person participating in the survey. verbal consent will be obtained and we will explain that their academic standing will not be affected by their answers to the survey. we will carefully explain that their participation in the survey is voluntary. all surveys will contain the names and contact information of the investigators. the survey will be administered under the direction of the researchers by the researchers and/or their trained research team.

Eligibility criteria:
inclusion criteria: * all mothers and health care workers willing to fill out survey in and around ogbomoso, nigeria exclusion criteria: * all mothers and health care workers not willing to fill out survey in an around ogbomoso, nigeria
forced oscillation technique (fot) and expiratory flow limitation (efl)

Conditions: COPD

Summary: the aim of this study is to distinguish copd patients with expiratory flow limitation in body plethysmography (open loop) from the patients without expiratory flow limitation in body plethysmography (closed loop) with the obtained fot parameters.

in daily practice the expiratory flow limitation is measured by body plethysmography. an open loop in body plethysmography shows expiratory flow limitation in copd patients. but body plethysmography requires that the patient quietly sits in a closed box and is not able to follow changes breath by breath. the goal of this study is to validate the forced oscillation technique (fot) for measuring expiratory flow limitation in copd patients.30 copd patients with an open loop in body plethysmography are compared to 30 copd patients with a closed loop. the methods used in this study are the maximal overlap discrete short time fourier transform (modft) combined with a total least squares analysis. it is hypothesized that the obtained fot parameters are able to distinguish the patients with expiratory flow limitation in body plethysmography from the patients without expiratory flow limitation in body plethysmography.secondary study questions are: 1) to what extend are the fot parameters distorted by breathing artifacts and measurement noise. 2)what changes can be detected by fot in expiratory flow limitation after administration of salbutamol.

Eligibility criteria:
inclusion criteria: * presenting to the outpatient clinic * age 50-80 years * diagnosed with copd according to the standard criteria * gold stage ii to iv copd * current or ex-smokers (at least 10 py) * stable disease (no current exacerbation or exacerbation during the 4 weeks previous to the inclusion) exclusion criteria: * history of exacerbation of copd in the preceding month * upper airway obstruction * allergic asthma * osas (obstructive sleep apnea syndrome) * extreme obesity (bmi\>35) * clinically manifest cardiac disease (for example clinically relevant congestive heart failure, unstable angina pectoris)

Keywords: forced oscillation technique (fot) expiratory flow limitation (efl) breathing artifacts copd
risk factors of rebleeding after peptic ulcer bleeding: a nationwide cohort study

Conditions: Peptic Ulcer Bleeding

Summary: the purpose of the investigators study is to investigate the factors associated with rebleeding in patients with peptic ulcer bleeding.

the investigators are performing a nationwide population based cohort study to investigate the factors associated with rebleeding in patients with peptic ulcer bleeding. the results of the investigators study should give us information about patients who are at high risk of rebleeindg and enable us to manage these patients appropriately.

Eligibility criteria:
inclusion criteria: * patients diagnosed with peptic ulcer bleeding by endoscopy * patients who consent to be enrolled in the study exclusion criteria: * patients who refuse to be enrolled in the study

Keywords: peptic ulcer bleeding rebleeding mortality nationwide
a study of islatravir (mk-8591) in anti-retroviral therapy-naive, human immunodeficiency virus-1 infected participants (mk-8591-003)

Conditions: HIV-1

Summary: this study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral therapy (art) activity of islatravir (mk-8591) monotherapy in art-naive, human immunodeficiency virus-1 (hiv-1) infected participants. the primary hypothesis is that at a safe and tolerable dose of islatravir, the true mean difference in the plasma hiv-1 ribonucleic acid (rna) reduction from baseline between islatravir and placebo is at least 0.5 log (base10) copies/ml.


Eligibility criteria:
inclusion criteria: * non-pregnant, non-breast feeding, postmenopausal or surgically sterile female * female with reproductive potential agrees to use (or have male partner use) two acceptable methods of birth control * male agrees to use acceptable method of contraception during study and for 90 days after last dose of trial drug * has stable baseline health, other than hiv infection * has no significantly abnormal electrocardiogram * is hiv-1 positive * have a screening plasma hiv-1 rna ≥ 10,000 copies/ml within 30 days prior to the treatment phase of this study. for inclusion in panel islatravir extended observation, participants must also have a screening plasma hiv-1 rna ≤ 25,000 copies/ml within 30 days prior to the treatment phase. * is art naive * has not received any investigational agent or marketed art within 30 days of trial drug administration * is diagnosed with hiv-1 infection \>= 3 months prior to screening * is willing to receive no other art during treatment phase of study * has no evidence of mutations conferring resistance to nucleoside reverse transcriptase inhibitors (nrtis) exclusion criteria: * is mentally or legally institutionalized/incapacitated, or has significant emotional problems, or has a history of clinically significant psychiatric disorder of the last 5 years * has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of hiv-1 infection), renal, respiratory, genitourinary, major neurological abnormalities or diseases * has a history of cancer (malignancy) * has a history of significant multiple and/or severe allergies, or had an anaphylactic reaction to drugs or food * is positive for hepatitis b surface antigen * has a history of chronic hepatitis c * had major surgery or lost 500 ml of blood with 4 weeks prior to screening visit * has participated in another investigational trial within 4 weeks prior to dosing visit * will use any medications, prescribed drugs, or herbal remedies 4 weeks prior to dosing of trial drug, up to the post-trial visit * consumes excessive amounts of alcohol, caffeinated beverages, or tobacco products * uses illicit drugs or has a history of drug abuse within the prior 2 years
assessment of automatic tourniquets for soldiers during wartime

Conditions: Trauma Injury; Hemorrhage Wound

Summary: the goal of this clinical trial is to compare usability and performance of automatic tourniquets (aut) and standard mechanical tourniquets (cat) in healthy adults. the main questions it aims to answer are: * are auts effective in occlusion of blood flow * are auts easy to use participants will be asked to place aut and cat on their upper limbs and lower limbs (8 applications overall). following each application, the following parameters will be assessed: 1. limb blood flow 2. ease of use researchers will compare the results of the aut and cat to see if aut is as effective as cat in blood occlusion, and if aut is easy to use as the cat.

the goal of this clinical trial is to compare usability and performance of automatic tourniquets (aut) and standard mechanical tourniquets (cat) in healthy adults. the main questions it aims to answer are: * are auts effective in occlusion of blood flow * are auts easy to use participants will be asked to place aut and cat on their upper limbs and lower limbs (8 applications overall).

Eligibility criteria:
inclusion criteria: -soldier in active service or active reserve service. exclusion criteria: * muscle disorders * peripheral nerve disorders * skin diseases of the limbs * limb surgery in the past * rickets * hypertension
augmented infant resuscitator to enhance newborn ventilation

Conditions: Asphyxia Neonatorum; Birth Asphyxia; Perinatal Asphyxia

Summary: augmented infant resuscitator (air) is an inexpensive add-on, compatible with nearly every existing bag-valve mask and many types of ventilation equipment. air monitors ventilation quality and provides real-time objective feedback and actionable cues to clinicians to both shorten training times and improve resuscitation quality, adoption, retention, and confidence.

longitudinal, randomized control trial that examined the effectiveness of air among 270 participants, with 1,080 recorded ventilation scenarios, and across 20 sites in uganda and the u.s. birth attendants - including a mix of midwives, nurses, respiratory therapists, pediatricians, and neonatologists - with recent hbb and/or nrp training were recruited to participate in this randomized control trial. participants ventilated training mannequins for a fixed duration of time. participants were randomized to receive visual feedback from air (intervention) or have the air feedback covered (control). they were then requested to administer effective ventilation and verbally assess the mannequin condition. all mannequins appeared to be identical, but each session's mannequin was randomly selected with an upper airway that was normal, partially leaking, or partially obstructed.

Eligibility criteria:
inclusion criteria: * midwives, nurses, respiratory therapists, pediatricians, and neonatologists working as birth attendants in select hospitals in uganda and the u.s. who are either previous trained in helping babies breathe (hbb) and/or have a current newborn resuscitation program (nrp) certification. exclusion criteria: * none
kesimpta® (ofatumumab) in swiss multiple sclerosis patients - an observational study

Conditions: Multiple Sclerosis

Summary: this is a multi-center, observational study carried out in switzerland that aims to describe the effects of ofatumumab in a setting of routine medical care.

this non-interventional study will observe the effect of ofatumumab treatment compared to the standard of care (soc) arm of a closely monitored phase-iiib study (sthenos-comb157g3301) in ms patients in a real-world setting in switzerland over an observational period of 12 month.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained before participating in the study. 2. diagnosis of rms per mcdonald criteria (2017) occurred within 3 years prior to initiation of ofatumumab. 3. adult patients who have been on treatment with ofatumumab for at least 3 months, but not longer than 12 months prior to inclusion in the study. 4. ofatumumab treatment in line with the swiss kesimpta® label (i.e. adult patients with active, relapsing forms of ms) 5. patient is willing and able to complete patient diary during course of the study, as well as to complete pro questionnaires. exclusion criteria: 1. use of investigational drugs during the study, or between ofatumumab initiation and inclusion into the study, or within 3 months before ofatumumab initiation, or within 5 half-lives of investigational drug before ofatumumab initiation, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. 2. subjects who are not able to provide consent due to incapable judgement

Keywords: nis multiple sclerosis ms kosmos ofatumumab kesimpta
the nutritional status and food intake of community health agents

Conditions: Nutritional and Metabolic Diseases

Summary: this research had as a goal to characterize the social demographic profile, nutritional status, the presence of chronic non-transmissible diseases and food intake of the community health agents who belong to five family health units in the east zone of sao paulo city.

it's a descriptive, exploratory and quantitative study developed among 88 individual.

Eligibility criteria:
inclusion criteria: * be an agent comunnity health who belong in the family health unit choosed to participate of this study; * assign the autorization to participate of the study; * answer a questionary of health, social demographic profile and food intake. exclusion criteria: * refuse to participate or assign the autorization; * don´t answer the questionary of health and food intake; * don´t participate of the nutricional status evaluation.

Keywords: family health program; food consumption; nutritional status
the blood patch in the management of intracranial hypotension

Conditions: Intracranial Hypotension

Summary: intracranial hypotension results from leakage and/or hypotension of cerebrospinal fluid. it can be spontaneous or secondary to a dural puncture complicating perimedullary anesthesia or a lumbar puncture. the incidence remains low with less than 1% post spinal puncture (25 gauge needle), but is observed more frequently following a lumbar puncture, up to 36% with a 20 or 22 gauge needle. accidental puncture of the dura mater with a 17 gauge needle used for epidural anesthesia is associated with postpuncture headaches in 75-80% of cases. classically, symptoms appear 24 to 48 hours after the puncture and consist of very intense, postural, fronto-occipital headaches which may be associated with cranial nerve symptoms such as visual or hearing disturbances or vertigo. among the risk factors are the size and type of the needle, age under 60 and female gender. about 90% of pdph are self-limiting within 7-10 days.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject having benefited from a bloodpatch between 01/01/2021 and 12/31/2022 exclusion criteria: - subject (and/or their legal representative if applicable) having expressed their (their) opposition to the reuse of their data for scientific research purposes

Keywords: intracranial hypotension post-dural puncture headache cranial nerve symptoms hearing disturbances vertigo
a comparative study of the treatment of real-world patients with clear cell carcinoma of the ovary

Conditions: Ovarian Clear Cell Carcinoma

Summary: the goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ici)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (occc), and compare the treatment response with the phase ii, single-arm clinical trial inova to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. the main questions it aims to answer are: * what is the efficacy of physician's choice of chemotherapy in relapsed/refractory occc patients in the real world? * is ici-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory occc patients? * dose the combinational regimens of sintilimab plus bevacizumab in sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (inova) trial more effective than physician's choice of chemotherapy? participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (ehr)-derived data.


Eligibility criteria:
inclusion criteria: 1. female patients with age ≥ 18 years old and ≤ 75 years old. 2. there must be a histological diagnosis of ovarian clear cell carcinoma. 3. patients with recurrent or persistent ovarian clear cell carcinoma must have at least one-line pretreated platinum-containing chemotherapy. 4. eastern cooperative oncology group (ecog) performance status score ≤ 2. 5. expected survival time ≥ 12 weeks. exclusion criteria: 1.histological evidence of non-ovarian clear cell carcinoma.

Keywords: ovarian clear cell carcinoma real world study immune checkpoint inhibitor
sleep disorders in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: fatigue is a frequent and disabling symptom in patients with multiple sclerosis (ms). the pathophysiology of this sign is not fully understood. some data suggest that the fatigue is associated with sleep disorders. the aim of this study is to determine the polysomnographic parameters in ms patients with fatigue in comparison to ms patients without fatigue.


Eligibility criteria:
inclusion criteria: * patients with multiple sclerosis * expanded disability status scale score \< or = 5 * fatigue (modified fatigue impact scale \> 45), with a disease duration \> 3 months exclusion criteria: * depression * cognitive disorders * edss \> 5 * epilepsia * obesity * drug inducing sleep disorders

Keywords: multiple sclerosis fatigue sleep disorders
reproducibility of strength testing and functional testing of the hip for the return to sport of patients activated by a femoroacetabular impingement: comparison between a group of patients and a group of healthy controls

Conditions: Femoroacetabular Impingement

Summary: reproducibility of strength testing and functional testing of the hip for the return to sport of patients activated by a femoroacetabular impingement: comparison between a group of patients and a group of healthy controls femoroacetabular impingement is a disorder movement-related hip clinic, with bone abnormality at the joint coxo-femoral associated with a triad of symptoms, clinical signs and findings imagery. it represents premature contact symptomatic between the femur and the acetabulum. currently, there is no consensus for determine when to return to sport securely after processing arthroscopy of a emoroacetabular impingement. various clinical tests are used to assess the mobility or pain but no test studies specifically the level of recovery functional.

reproducibility of strength testing and functional testing of the hip for the return to sport of patients activated by a femoroacetabular impingement: comparison between a group of patients and a group of healthy controls femoroacetabular impingement is a disorder movement-related hip clinic, with bone abnormality at the joint coxo-femoral associated with a triad of symptoms, clinical signs and findings imagery. it represents premature contact symptomatic between the femur and the acetabulum. currently, there is no consensus for determine when to return to sport securely after processing arthroscopy of a emoroacetabular impingement. various clinical tests are used to assess the mobility or pain but no test studies specifically the level of recovery functional.

Eligibility criteria:
inclusion criteria: patients * male or female aged 16 to 50 * occurrence of the injury requiring surgery during a sports activity * hip arthroscopy * surgery performed by surgeons from the santy orthopedic center (lyon) * angle alpha \> 55° * patient having signed an informed consent * affiliated subject or beneficiary of a social security control group * male or female aged 16 to 50 * practicing a regular sporting activity in both groups * patient having signed an informed consent * affiliated subject or beneficiary of a social security exclusion criteria: patient group * contraindication of the surgeon * present another pathology of the hip on the side of the operated limb or on the contralateral side control group * declare a history of lower limb pain/injury in the last 12 months * declare a history of orthopedic surgery on the lower limbs in any case will be excluded protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.

Keywords: femoroacetabular impingement reproducibility of strength testing and functional testing
application of botulinum toxin type a in salivary glands in the treatment of drooling in patients with cerebral palsy

Conditions: Sialorrhea; Cerebral Palsy

Summary: the purpose of this study is to evaluate the safety and efficacy of botulinum toxin-a in salivary glands as a treatment for decrease drooling in patients with cerebral palsy and evaluate the long-term effects and tolerance . to assess whether patients with cerebral palsy have hypersalivation comparing with patients without treatment and healthy volunteers and if botulinum toxin may reduce the volume of drooling without altering the swallowing function.

patients with cerebral palsy (cp) and other neurological diseases ( parkinson´s disease (pd), bulbar amyotrophic lateral sclerosis, neurodegenerative diseases, idiopathic hypersalivation, head and neck carcinomas, etc) frequently have lifelong issues with oral motor control that may present as eating, drinking difficulties, drooling and/or speech problems. inadequate saliva control occurs in approximately 30% of patients with cp. drooling usually caused by swallowing dysfunction and can lead to choking, salivary aspiration, pneumonia, chest infections,chronic irritation of the facial skin, and /or dehydration, in some cases the person loss of self esteem and impede community inclusion. numerous therapies, anticholinergic medication, surgery, etc, have all been used to reduce drooling with varying side effects and degrees of success, but none with optimal results. systemic anticholinergics may reduce salivary secretion but are frequently not tolerated by the patients because they have multiple side effects. recently botulinum toxin type a has been used in the treatment of sialorrhea, in clinical studies have found that botulinum toxin type-a may have a good response with fewer side effects.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cerebral palsy ( medical history, neurological examination,magnetic resonance * patients with disorders for eating, drinking, pneumonia, irritation of the skin face, social exclusion * score of \>3 on drooling severity and frequency scale exclusion criteria: * patients under 18 years * swallowing disorders * diagnosis of myasthenia, eaton lambert syndrome, amyotrophic lateral sclerosis or diseases that interfere with the function neuroglandular * pregnant or lactating period * patients without informed consent

Keywords: drooling cerebral palsy